Colloidal Silver, Treatment of COVID-19
- Conditions
- SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Drug: Placebo
- Registration Number
- NCT04978025
- Lead Sponsor
- Hôpital Universitaire Sahloul
- Brief Summary
Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.
Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I
- Detailed Description
Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.
Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy.
The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
- Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.
- Any pregnant or breastfeeding woman
- patient with an expectation of survival of less than 24 hours
- Dyspnea leading to heart failure
- Hepatic insufficiency
- Chronic respiratory failure
- Renal failure, clearance <20ml • min-1 • 1.73 • m-²
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Group Placebo * Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days * By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days. Silver Group Colloidal Silver * Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon) * By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
- Primary Outcome Measures
Name Time Method Chage of clinical status 10 DAYS the distribution of clinical status assessed on the 7-point ordinal scale on day 10 of the study
- Secondary Outcome Measures
Name Time Method Adverse events ON 1 month adverse events throughout the study period
the duration of the different respiratory assistance modes ON 11 days the duration of the different respiratory assistance modes
the duration of hospitalization ON 11 days number of days of hospitalization
all-cause mortality ON 1 month the cause and the date of Death
Trial Locations
- Locations (1)
HU Sahloul, sousse, Tunisia
🇹🇳Sousse, Itinéraire Ceinture Cité Sahloul, Tunisia